Premium
Biochemical and in vivo properties of commercial virus‐inactivated factor VIII concentrates
Author(s) -
Berntorp Erik,
Nilsson Inga Marie
Publication year - 1988
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1988.tb00825.x
Subject(s) - von willebrand factor , von willebrand disease , in vivo , factor ix , virus , chemistry , solvent , chromatography , microbiology and biotechnology , medicine , virology , immunology , biology , biochemistry , platelet
The following commercial virus‐inactivated factor VIII concentrates were studied in vitro: AHF‐Kabi and Octonativ, KabiVitrum; Hemofil T, Hyland; Factorate HP and Monoclate, Armour; Nordiocto, Nordisk Gentofte (dry heated); Kryobulin TIM3, Immuno (steam treated); Profilate, Alpha (heated as dry material slammed in heptane); Hemate P, Behring (wet heated) and Octa‐V.I., Octapharma (solvent/detergent treated). The concentration of VIII:C was lowest in AHF‐Kabi, whereas it ranged from 24 to 53 IU/ml in the high purity concentrates, except for Monoclate in which it ranged from 91–128 IU/ml. All concentrates but Octa‐V.I. had higher values for VIILAg than for VIII:C. von Willebrand factor with normal distribution of multimers could only be demonstrated in AHF‐Kabi and Hemate P. In vivo studies were performed in 12 severe hemophiliacs. Recovery and half‐life of VIILC did not differ between the various concentrates. Hemate P was given to 5 patients with severe von Willebrand's disease, in all of whom a correction of the hemostatic defect was seen.